Galectin-4, also known as LGALS4, is a member of galectin family, a family of conserved animal lectins, which are characterized by their affinity for poly-N-acetyllactosamine-enriched glycoconjugates and sequence similarities in the carbohydrate recognition domain (CRD). Galectin-4 was initially identified in gastrointestinal mucosa including oral mucosa and esophagus. RNAse protection assays revealed that it is not expressed in the brain, kidney, skeletal muscle, heart, liver, and lung tissues. Similar to other galectins, galectin-4 does not have a signal peptide and is synthesized as a cytosolic protein, but it can be secreted. Galectin-4 controls intestinal inflammation and it binds to activated T cells at the CD3 region, which results in a potent inhibition of cell cycle progression and induction of antigen-induced cell death. Galectin-4 induces T cell death through the caspase-independent calcium-calpain signaling pathway. Galectin-4 is downregulated in colon cancer tissue and is absent in invasive carcinomas. Nevertheless, high levels in serum are detected in patients with colon and breast cancer. In contrast, it is considerably upregulated in pancreatic adenocarcinomas, hepatocellular carcinomas, and gastric cancer.

PRODUCT DETAILS

Clone: A15102C

Antibody Type: Monoclonal

Reactivity: Human

Format: Alexa Fluor 647

Host: Mouse

Isotype: IgG2b, κ

Applications: IHC-P - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.